GlassScriptPhysician profile
Michael V Calvin
NPI 1477707610
$4,550.82
in general payments reported to CMS, 2019-2025
20 companies · $107 in 2025
The $107 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,439 · 2022: $1,299 · 2023: $1,555 · 2024: $151 · 2025: $107.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,774 · Consulting Fee: $33.00 · Education: $6.23.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,774.03 |
| Consulting Fee | $33.00 |
| Education | $6.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,463.51 | 2021-2023 | Airsupra, Tezspire, Fasenra |
| Csl Behring | $1,026.06 | 2021-2023 | Hizentra, Haegarda, Privigen |
| Glaxosmithkline, LLC. | $476.11 | 2021-2025 | Nucala |
| Takeda Pharmaceuticals U.S.A., INC. | $400.67 | 2021-2023 | Takhzyro |
| Genzyme Corporation | $337.94 | 2022-2024 | |
| Grifols USA, LLC | $238.80 | 2021-2024 | Xembify, Prolastin-C Liquid |
| Regeneron Healthcare Solutions, INC. | $101.64 | 2024-2025 | Dupixent |
| Biocryst US Sales Co., LLC | $96.14 | 2021-2023 | Orladeyo |
| Bio Products Laboratory USA, INC. | $74.43 | 2022-2023 | Coagadex, Gammaplex |
| Incyte Corporation | $56.68 | 2021-2023 | Opzelura |
| Blueprint Medicines Corporation | $48.74 | 2021-2023 | Ayvakit |
| Kaleo, INC. | $39.50 | 2022-2023 | Auvi-Q |
| Adma Biomanufacturing LLC | $33.00 | 2023 | |
| Octapharma USA, INC. | $30.69 | 2022 | |
| Novartis Pharmaceuticals Corporation | $26.67 | 2024 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharming Healthcare, INC. | $25.98 | 2021 | |
| Tersera Therapeutics LLC | $21.30 | 2023 | Quzyttir |
| Optinose US, INC. | $19.83 | 2021 | |
| Uswm, LLC | $19.00 | 2021 | |
| Pfizer INC. | $14.13 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Calvin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.